Prescribing Information
Learn more
This educational programme, sponsored and organised by A. Menarini Farmaceutica Internazionale SRL, has been designed by an independent panel of expert cardiologists with the aim of gaining insight on recent advances in the management of stable angina pectoris.
Learning objectives:
The diagnosis and management of different forms of presentation of stable angina.
Recent developments regarding guidelines, major publications on chronic coronary syndromes, and diagnostic and therapeutic algorithms.
Gain better understanding on the use of tests for the diagnosis of INOCA and other CCS – Coronary physiology studies and Cardiac Magnetic Resonance Imaging.
Evidence based management of Refractory Angina.
If – as we truly hope – you wish to participate, please register yourself by clicking on the following:
Please note that registration will be open until the day of the event.
Certificates of Attendance will be granted.
I hope you will engage in fruitful discussion with the faculty during the meeting to try to identify suitable and feasible ways of improving patient management in stable angina.
The virtual meeting will be interactive featuring Clinical and Interventional Cardiologists.
On behalf of the Faculty and A. Menarini Farmaceutica Internazionale SRL, a warm welcome and we hope you will enjoy the meeting.
Kind regards, Adrian Brady Prof Adrian Brady
Chair, on behalf of A. Menarini Farmaceutica Internazionale SRL.
This promotional meeting is organised and funded by A. Menarini Farmaceutica Internazionale SRL and will involve discussion of Ranexa (ranolazine).
Ranexa (ranolazine) Prescribing Information
Ranexa (ranolazine) is approved for licensed use by ESC & NICE Guidance. Currently SMC does not recommend use within NHS Scotland.
Agenda
| Time | Session | Speaker |
|---|---|---|
| 17.30 | Welcome & Introduction | Professor Adrian Brady |
| 17.35 | The need for a paradigm change in the pharmacological management of angina | Professor Juan Carlos Kaski |
| 17.55 | Diagnosis and management of angina with no obstructive coronary artery disease | Professor Colin Berry |
| 18.15 | An Audit of The Use of Ranolazine in Patients with Refractory Angina | Professor Chim Lang |
| 18.35 | Q&A | All Faculty |
| 18.50 – 18.55 | Chair Close |
Speakers
Professor Adrian Brady
BSc (Hons, summa cum laude), MD, FRCP (Glasg), FRCPE, FBHS, FESC, FAHA Honorary Professor of Cardiology at the University of Glasgow, Consultant Cardiologist, Glasgow Royal Infirmary, and Visiting Professor of Cardiology at the Mayo Clinic and the Cleveland Clinic, USA. Professor Brady’s major specialities are the clinical aspects and epidemiology of hypertension, lipids, coronary heart disease and pulmonary embolism.
Professor Juan Carlos Kaski
DSc, MD, DM (Hons), FRCP, FESC, FACC, FAHA
Professor of Cardiovascular Science at St George’s University of London, Immediate Past Chairman of the Cardiovascular and Cell Sciences Research Institute at SGUL, Fellow of the Royal College of Physicians, the American College of Cardiology, the European Society of Cardiology, the American Heart Association, and many other major scientific societies worldwide.
Professor Kaski’s main areas of research include microvascular angina, inflammatory and immunological mechanisms of atherosclerosis, biomarkers of cardiovascular risk and coronary artery spasm.
Professor Colin Berry
Sc, MB, ChB, PhD, FRCP(Glasg), FACC
Chair in Cardiology and Imaging in the University of Glasgow. He is Director of Research in the Golden Jubilee National Hospital and a Consultant Cardiologist in this hospital and in the Queen Elizabeth University Hospital in Glasgow. Professor Berry is currently an Executive Editor of the European Heart Journal, Senior Consultant Editor of Euro Intervention and Editorial Board member of the Cardiovascular Research journal. He is President-Elect of the British Society of Cardiovascular Magnetic Resonance, Research Lead and Board Member of the British Cardiovascular Intervention Society.
Professor Chim Lang
MD, FRCP (Lond), FRCP (Edin), FACC, FESC
Consultant Cardiologist and clinical pharmacologist and Professor of Cardiology at University of Dundee. Professor Lang leads an integrated cardiovascular research laboratory dedicated to translational research and in the development of biomarkers and novel treatment strategies in patients with cardiovascular diseases.
Further biography information on the faculty is available on registration.
PP-RA-UK-0615
Date of Prep: Apr 21
